Schneider, Elizabeth
Spetter, Maartje S.
Martin, Elizabeth
Sapey, Elizabeth
Yip, Kay Por
Manolopoulos, Konstantinos N. http://orcid.org/0000-0001-8890-6090
Tahrani, Abd A.
Thomas, Jason M. http://orcid.org/0000-0001-7013-8994
Lee, Michelle
Hallschmid, Manfred http://orcid.org/0000-0002-0352-1106
Rotshtein, Pia
Dourish, Colin T. http://orcid.org/0000-0002-3403-6330
Higgs, Suzanne http://orcid.org/0000-0002-9225-7692
Article History
Received: 6 January 2022
Revised: 17 March 2022
Accepted: 21 March 2022
First Online: 9 April 2022
Competing interests
: AAT reports grants from Novo Nordisk, personal fees from Novo Nordisk, non-financial support from Novo Nordisk, personal fees from Eli Lilly, non-financial support from Eli Lilly, personal fees from Janssen, personal fees from AstraZeneca, non-financial support from AstraZeneca, non-financial support from Impeto medical, non-financial support from Resmed, non-financial support from Aptiva, personal fees from Boehringer Ingelheim, non-financial support from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, nonfinancial support from Bristol Myers Squibb, personal fees from NAPP, non-financial support from NAPP, personal fees from Merck Sharp & Dohme, non-financial support from Merck Sharp & Dohme, personal fees from Nestle, personal fees from Gilead, grants from Sanofi, and personal fees from Sanofi outside the submitted work. AAT is currently an employee of Novo Nordisk. This work was performed before AAT became a Novo Nordisk employee. Novo Nordisk had no role in this study. CTD is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. All other authors declare no competing interests.